Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
Pfizer Inc. reports developments across its global biopharmaceutical business, including prescription medicines, vaccines, biosimilars, sterile injectables, and oncology therapies. Recurring news covers financial results and guidance, commercial portfolio changes within Biopharma, dividend declarations, capital allocation priorities, and product access initiatives for established medicines such as Eliquis.
Company updates also address clinical and regulatory activity across Pfizer's pipeline and marketed products. Recent themes include oncology data presentations, Phase 3 results for ELREXFIO in relapsed or refractory multiple myeloma, PADCEV combination regulatory activity in bladder cancer, VYNDAMAX patent litigation settlements, and shareholder meeting communications.
Pfizer Inc. (NYSE: PFE) is hosting a webcast discussion with Chief Scientific Officer Mikael Dolsten and Chief Development Officer William Pao at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 15, 2022, at 8:40 a.m. PDT. Interested parties can access the webcast at www.pfizer.com/investors. The transcript will be available within 24 hours and accessible for at least 90 days. Pfizer focuses on innovative therapies and vaccines to enhance patient lives and actively engages in global health initiatives.
Pfizer Inc. (NYSE: PFE) announced a $120 million investment to expand its manufacturing capabilities at the location value="LU/us.mi.kalzoo"Kalamazoo, Michigan facility, creating over 250 high-skilled jobs. This initiative aims to enhance production of active pharmaceutical ingredients (APIs) for PAXLOVID, its COVID-19 oral treatment. Since 2017, Pfizer has invested $5 billion in U.S. manufacturing. The Kalamazoo site will become one of the world’s largest API producers, boosting the supply capacity of PAXLOVID to meet growing global demand.
Pfizer Inc. (NYSE:PFE) announced overall survival results from the Phase 3 PALOMA-2 trial evaluating IBRANCE® (palbociclib) with letrozole in first-line treatment for postmenopausal women with HR+, HER2- metastatic breast cancer. With a median follow-up of 90 months, the study showed a median overall survival of 53.9 months for the treatment group versus 51.2 months for the control, though the results were not statistically significant (HR=0.956). The trial's primary endpoint was progression-free survival, previously met in 2016.
Pfizer announced plans to exit its 32% ownership interest in Haleon, the new standalone company formed post-GSK demerger. This move aims to maximize shareholder value. The demerger, involving GSK transferring approximately 80% of its consumer healthcare business to GSK shareholders, will be completed by July 2022. Haleon will also pursue a listing on the New York Stock Exchange. Key legal and financial advisors, including Morgan Stanley and Guggenheim Securities, are engaged in the process. This strategic decision aligns with Pfizer's focus on innovative medicines and vaccines.
Pfizer Inc. (NYSE: PFE) will host a live webcast on June 6, 2022 at 3:45 p.m. EDT featuring Angela Hwang and Aamir Malik discussing initiatives on expanding access and affordability for Pfizer’s medicines and vaccines. Investors can register and access the webcast via Pfizer's investor website. A transcript will be available within 24 hours post-event. The company emphasizes its commitment to quality healthcare and responsible collaboration worldwide.
Pfizer (NYSE: PFE) announced that its investigational therapy ervogastat (PF-06865571) and clesacostat (PF-05221304) for treating non-alcoholic steatohepatitis (NASH) with liver fibrosis has received Fast Track designation from the FDA. This designation aims to expedite the review of therapies addressing unmet medical needs. Phase 2a trial results showed a significant reduction in liver fat and a favorable safety profile. Pfizer is also conducting an ongoing Phase 2 trial (NCT04321031), with results expected in 2024, which will inform potential Phase 3 development.
Pfizer Inc. (NYSE: PFE) will host a webcast featuring CEO Albert Bourla at the Bernstein 38th Annual Strategic Decisions Conference on Wednesday, June 1, 2022, at 9:00 a.m. EDT. Interested parties can access the live event and subsequent replay on Pfizer's investor website, available at www.pfizer.com/investors, starting today. A transcript and replay will be accessible for 90 days following the event. Pfizer emphasizes its commitment to improving patient health through innovative therapies and ongoing support for affordable healthcare worldwide.
Pfizer has launched 'An Accord for a Healthier World', aiming to provide patent-protected medicines and vaccines on a not-for-profit basis to 1.2 billion people in 45 lower-income countries. This initiative includes partnerships with five initial countries: Rwanda, Ghana, Malawi, Senegal, and Uganda. Key objectives include improving healthcare infrastructure and access to essential medicines to reduce health inequities. Pfizer will offer 23 medicines and vaccines, with future products added to the Accord as they become available.
Pfizer announces the launch of ‘An Accord for a Healthier World’, providing its patented medicines and vaccines on a not-for-profit basis to 1.2 billion people across 45 lower-income countries. The initiative aims to address health inequities and includes collaboration with health officials from Rwanda, Ghana, Malawi, Senegal, and Uganda. Pfizer commits to making available 23 medicines and vaccines and streamlining regulatory pathways to improve access. The Accord emphasizes global health equity, with potential impacts on the lives of nearly one million annually in these regions.
Pfizer Inc. (NYSE: PFE) announced successful results from two pivotal studies of etrasimod for moderately-to-severely active ulcerative colitis (UC) at Digestive Disease Week 2022. Both Phase 3 trials, ELEVATE UC 52 and ELEVATE UC 12, met all primary and key secondary endpoints, showing significant improvement in clinical remission rates. In ELEVATE UC 52, 32.1% of patients on etrasimod achieved clinical remission at week 52 versus 6.7% for placebo. Safety profiles were consistent with previous studies. Regulatory filings are anticipated later this year.